TKT to Report Second Quarter Financial Results on August 3, 2004

Search Blogs that Mention this News Release

Click this link to view linked Bookmarking Services

Click this link to view linked Blogging Services

TKT to Report Second Quarter Financial Results on August 3, 2004

		TRANSKARYOTIC THERAPIES LOGO - TKT Transkaryotic Therapies Inc. logo. (PRNewsFoto)[JL] CAMBRIDGE, MA USA

    CAMBRIDGE, Mass., July 27 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) will report second quarter 2004 financial
results on Tuesday, August 3, 2004 before the open of U.S. financial markets.
In connection with this announcement, TKT will host a conference call and live
audio webcast on August 3, 2004 at 10:00 a.m. Eastern Time to discuss these
financial results, the company's financial guidance and the company's business
generally.  Participants may access the call by dialing (913) 981-5592.  This
call will also be broadcast live over the Internet at http://www.tktx.com
under the Investor Information section.
    A replay of this conference call will be available for two weeks,
beginning Tuesday, August 3, 2004 at 1:00 p.m. Eastern Time by dialing (719)
457-0820 and using the access code 771615.  In addition, a replay of the
webcast will be archived on the TKT website in the Investor Information
section.

    About TKT
    Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies.  Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease.  In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union.  TKT was founded in 1988 and is headquartered in
Cambridge, Massachusetts, with additional operations in Europe, Canada and
Latin America.  Additional information about TKT is available on the company's
website at http://www.tktx.com.

    Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Aventis Pharmaceuticals, Inc.

    CONTACT:
     Daniella M. Lutz
     Corporate Communications Manager
     (617) 349-0205

SOURCE Transkaryotic Therapies, Inc.

http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
Company News On-Call:

http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz, Corporate Communications
Manager of Transkaryotic Therapies, Inc., +1-617-349-0205